CLLS - Rasio utang marang kapitalisasi buku Cellectis SA

Logo korporat perusahaan cellectis.com (CLLS)

Cellectis S.A. (CLLS) faces production challenges for gene therapies due to the complexity of working with live cells, which limits process automation. The company leads in genome modification via the TALEN system, investing heavily in R&D. The business relies on an autonomous cycle independent of the broader economy, giving the asset defensive qualities. The current indicator is 2.66. This chart illustrates the company's valuation.

CLLS Cellectis SA: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 27.10.2026

Ringkesan rincian data analitis cellectis.com (CLLS)

- rega lan prakiraan konsensus rega:
Rega saham Cellectis|CLLS - Target konsensus
- data kapitalisasi pasar:
Nilai pasar CLLS|CLLS - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Cellectis S.A.|CLLS - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku cellectis.com|CLLS - Aset Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal Cellectis S.A.|CLLS - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Cellectis|CLLS - Utang kumulatif perusahaan|Utang marang nilai buku CLLS
Analisis kabeh metrik perusahaan:CLLS, Cellectis Biotherapeutics
Produk dadi Cellectis SA

This ratio determines the share of total liabilities within the equity structure, allowing for an assessment of the financial leverage level and the business's dependence on borrowed funds. Analyzing the extent to which balance sheet capital is covered by debt obligations serves as a stress test for the stability of Cellectis S.A. (CLLS), whose capital expenditures on gene editing robotization and laboratory automation require balanced financing to minimize default risks.

Pesaing Cellectis S.A.

Legend Biotech - Utang-utang marang kapitalisasi buku|sana.com - Utang marang nilai buku|AUTL (Autolus Therapeutics plc) - Rasio utang marang kapitalisasi buku|ALLO: Utang-utang marang nilai buku|Cartesian Therapeutics Inc (RNAC) - Rasio utang marang kapitalisasi buku|CRBU (Caribou Biosciences, Inc) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku TIL (Instil Bio, Inc.)|Utang-utang marang nilai buku Genenta|IPSC: Utang-utang marang kapitalisasi buku|Utang marang aset resik jaspertherapeutics.com JSPR|SNTI: Utang marang nilai buku|ADAP - Utang-utang marang nilai buku|Utang marang nilai buku CERo Therapeutics Holdings Inc. (CERO)|TCRT - Rasio utang marang aset resik|ACHL (achillestx.com) - Utang-utang marang kapitalisasi buku|CARGO Therapeutics Inc. (CRGX) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku PSTX (Poseida)|Utang-utang marang nilai buku TSVT|Rasio utang marang kapitalisasi buku Gracell Biotechnologies (GRCL)